We will be contrasting the differences between Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and Pacific Biosciences of California Inc. (NASDAQ:PACB) as far as institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paratek Pharmaceuticals Inc.	17.12M	11.63	112.36M	-3.64	0.00
Pacific Biosciences of California Inc.	78.63M	14.21	102.56M	-0.76	0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Paratek Pharmaceuticals Inc. and Pacific Biosciences of California Inc.

Profitability

Table 2 has Paratek Pharmaceuticals Inc. and Pacific Biosciences of California Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Paratek Pharmaceuticals Inc.	-656.31%	-132.5%	-44.6%
Pacific Biosciences of California Inc.	-130.43%	-88.1%	-57.7%

Volatility & Risk

Paratek Pharmaceuticals Inc. has a beta of 1.71 and its 71.00% more volatile than Standard & Poor’s 500. Competitively, Pacific Biosciences of California Inc.’s 140.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.4 beta.

Liquidity

The Current Ratio of Paratek Pharmaceuticals Inc. is 11.4 while its Quick Ratio stands at 11.4. The Current Ratio of rival Pacific Biosciences of California Inc. is 6.6 and its Quick Ratio is has 5.7. Paratek Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Pacific Biosciences of California Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for Paratek Pharmaceuticals Inc. and Pacific Biosciences of California Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Paratek Pharmaceuticals Inc.	0	0	4	3.00
Pacific Biosciences of California Inc.	0	3	0	2.00

The consensus target price of Paratek Pharmaceuticals Inc. is $21.25, with potential upside of 246.09%. Pacific Biosciences of California Inc. on the other hand boasts of a $7.25 consensus target price and a -2.03% potential downside. The results from earlier shows that analysts opinion suggest that Paratek Pharmaceuticals Inc. seems more appealing than Pacific Biosciences of California Inc.

Institutional & Insider Ownership

Roughly 77.7% of Paratek Pharmaceuticals Inc. shares are owned by institutional investors while 74.4% of Pacific Biosciences of California Inc. are owned by institutional investors. About 3.1% of Paratek Pharmaceuticals Inc.’s share are owned by insiders. Competitively, 2.3% are Pacific Biosciences of California Inc.’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Paratek Pharmaceuticals Inc.	-6.09%	0.67%	-8.98%	-32.44%	-46.95%	32.36%
Pacific Biosciences of California Inc.	0.14%	6.36%	-3.29%	67.27%	211.86%	-0.54%

For the past year Paratek Pharmaceuticals Inc. has 32.36% stronger performance while Pacific Biosciences of California Inc. has -0.54% weaker performance.

Summary

Pacific Biosciences of California Inc. beats on 7 of the 12 factors Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.